Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Pierre Benite – page 32

649 clinical trials in Pierre Benite, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Pierre Benite at a glance
649
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

649 trials in Pierre Benite

Open in trial search

Myelofibrosis

Not recruiting

Study on Treosulfan, Fludarabine Phosphate, and Thiotepa for Patients with Myelofibrosis Undergoing Haplo-identical Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Thiotepa
  • Sponsor:Assistance Publique Hopitaux De Paris

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Study of ponatinib and azacitidine combination treatment in patients with accelerated phase or blast crisis chronic myelogenous leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier De Versailles

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Systemic scleroderma

Not recruiting

Study on Itacitinib for Adults with Diffuse Systemic Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of Pembrolizumab with Drug Combination for Patients with Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Fallopian tube cancer+2

Not recruiting

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Relacorilant
  • Sponsor:Corcept Therapeutics Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Pierre Benite

What the registry says about research in the country

01 Infectious Diseases Research

Innovative clinical trials focusing on vaccine development against major viral infections. Studies include evaluations of new treatments for influenza, cytomegalovirus, and yellow fever.

  • Novel influenza vaccine efficacy testing
  • CMV prevention strategies
  • Yellow fever vaccine comparison studies

Research aims to enhance prevention and protection against these significant viral threats.

02 Gastrointestinal Disorders

Groundbreaking research in inflammatory bowel diseases, exploring innovative therapeutic approaches including fecal microbiota transplantation for both Crohn's disease and ulcerative colitis.

  • Crohn's disease treatment alternatives
  • Ulcerative colitis management
  • Microbiome-based interventions

Studies focus on developing alternative treatment strategies for patients with limited therapeutic options.

03 Oncology and Hematology

Comprehensive research into blood cancers and solid tumors, including multiple myeloma, leukemia, and advanced prostate cancer. Trials evaluate novel therapeutic combinations and targeted treatments.

  • Multiple myeloma treatment innovations
  • Prostate cancer therapy advancement
  • Leukemia treatment strategies

Focus on developing more effective and personalized treatment approaches.

04 Cardiovascular and Metabolic Disease

Studies addressing heart failure prevention, chronic kidney disease, and metabolic disorders. Research includes evaluation of novel drug combinations and therapeutic strategies.

  • Heart failure risk reduction
  • Kidney disease management
  • Obesity treatment studies

Emphasis on preventing disease progression and improving patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.